[go: up one dir, main page]

DK1303272T3 - Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom - Google Patents

Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom

Info

Publication number
DK1303272T3
DK1303272T3 DK01960284T DK01960284T DK1303272T3 DK 1303272 T3 DK1303272 T3 DK 1303272T3 DK 01960284 T DK01960284 T DK 01960284T DK 01960284 T DK01960284 T DK 01960284T DK 1303272 T3 DK1303272 T3 DK 1303272T3
Authority
DK
Denmark
Prior art keywords
disease
parkinson
alzheimer
treatment
benzothiazole derivatives
Prior art date
Application number
DK01960284T
Other languages
English (en)
Inventor
Alexander Alanine
Alexander Flohr
Aubry Kern Miller
Roger David Norcross
Claus Riemer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1303272T3 publication Critical patent/DK1303272T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DK01960284T 2000-06-21 2001-06-08 Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom DK1303272T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00113219 2000-06-21
PCT/EP2001/006506 WO2001097786A2 (en) 2000-06-21 2001-06-08 Benzothiazole derivatives

Publications (1)

Publication Number Publication Date
DK1303272T3 true DK1303272T3 (da) 2008-05-26

Family

ID=8169041

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01960284T DK1303272T3 (da) 2000-06-21 2001-06-08 Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom

Country Status (34)

Country Link
US (8) US6521754B2 (da)
EP (2) EP1797878A3 (da)
JP (1) JP3886897B2 (da)
KR (2) KR100526487B1 (da)
CN (1) CN1234358C (da)
AR (1) AR031244A1 (da)
AT (1) ATE385794T1 (da)
AU (2) AU8181701A (da)
BR (1) BR0112395A (da)
CA (1) CA2413086C (da)
CY (1) CY1107401T1 (da)
CZ (1) CZ2003182A3 (da)
DE (1) DE60132777T2 (da)
DK (1) DK1303272T3 (da)
EC (1) ECSP024399A (da)
ES (1) ES2299504T3 (da)
HK (1) HK1058148A1 (da)
HR (1) HRP20020962A2 (da)
HU (1) HUP0301315A3 (da)
IL (2) IL153278A0 (da)
JO (1) JO2503B1 (da)
MX (1) MXPA02012596A (da)
MY (1) MY138352A (da)
NO (2) NO324635B1 (da)
NZ (1) NZ522928A (da)
PE (1) PE20020104A1 (da)
PL (1) PL207384B1 (da)
PT (1) PT1303272E (da)
RU (1) RU2251419C2 (da)
SI (1) SI1303272T1 (da)
UY (1) UY26782A1 (da)
WO (1) WO2001097786A2 (da)
YU (1) YU96502A (da)
ZA (1) ZA200209730B (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8181701A (en) * 2000-06-21 2002-01-02 Hoffmann La Roche Benzothiazole derivatives
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
MXPA04004982A (es) * 2001-11-27 2004-08-11 Hoffmann La Roche Derivados de benzotiazol.
US6624163B2 (en) * 2001-11-29 2003-09-23 Hoffman-La Roche Inc. Benzothiazole derivatives
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6734179B2 (en) 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
US6713499B2 (en) 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
WO2003053954A1 (en) * 2001-12-12 2003-07-03 F. Hoffmann-La Roche Ag Benzothiophenes as adenosine receptor modulators
WO2003063876A2 (en) 2002-01-28 2003-08-07 Kyowa Hakko Kogyo Co., Ltd. Methods of treating patients suffering from movement disorders
PT1522314E (pt) * 2002-06-26 2014-06-05 Ono Pharmaceutical Co Medicamentos para doenças causadas pela contracção ou dilatação vascular
US6958420B2 (en) * 2002-07-19 2005-10-25 Board Of Trustees Of Michigan State University Synthesis of aminoarylboronic esters and substituted anilines from arenes via catalytic C-H activation/borylation/amination and uses thereof
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7094807B2 (en) 2002-11-19 2006-08-22 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and related compounds; inhibitors of viral replication
AR056615A1 (es) * 2002-12-27 2007-10-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de trastornos de la conducta
US7087761B2 (en) * 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
BRPI0406747A (pt) * 2003-01-13 2005-12-20 Hoffmann La Roche Derivados de benzoxazol e seu uso como ligandos de receptor de adenosina
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
WO2004101558A1 (en) * 2003-05-13 2004-11-25 F. Hoffmann-La Roche Ag 2-imidazo-benzothiazoles as adenosine receptor ligands
PL1636223T3 (pl) * 2003-05-19 2008-07-31 Hoffmann La Roche Pochodne benzotiazolu jako ligandy receptora adenozynowego
JP4408292B2 (ja) * 2003-05-21 2010-02-03 エフ．ホフマン−ラ ロシュ アーゲー ベンゾチアゾール誘導体、およびアデノシンａ２ａレセプターに関連する疾患の処置におけるその使用
AU2004243481B2 (en) * 2003-05-30 2008-10-09 F. Hoffmann-La Roche Ag Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine A2A receptor
EP1648862A2 (en) * 2003-07-10 2006-04-26 Achillion Pharmaceuticals, Inc. Substituted arylthiourea derivatives useful as inhibitors of viral replication
EA009480B1 (ru) * 2003-07-24 2008-02-28 Еуро-Селтик С. А. Гетероарил-тетрагидропиридины и их применение для лечения или профилактики боли
CL2004002015A1 (es) 2003-08-06 2005-05-13 Senomyx Inc Derivados de amida, productos que las contienen, utiles para modificar el sabor de alimentos y medicamentos.
BRPI0414266A (pt) 2003-09-19 2006-11-07 Hoffmann La Roche derivados de tiazolopiridina como ligandos receptores da adenosina
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
NZ550763A (en) * 2004-05-24 2010-07-30 Hoffmann La Roche 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
KR100834179B1 (ko) * 2004-05-24 2008-05-30 에프. 호프만-라 로슈 아게 4-하이드록시-4-메틸-피페리딘-1-카복실산(4-메톡시-7-모폴린-4-일-벤조티아졸-2-일)-아마이드
CN1989117B (zh) 2004-07-22 2011-01-19 弗·哈夫曼-拉罗切有限公司 取代的苯并噻唑
ATE457986T1 (de) * 2004-07-22 2010-03-15 Hoffmann La Roche Benzothiazolderivate
SE0401970D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
JP4633123B2 (ja) 2004-11-05 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー イソニコチン酸誘導体の製造方法
CA2602444C (en) 2005-03-23 2013-03-19 F.Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
KR101121292B1 (ko) 2005-09-27 2012-04-13 에프. 호프만-라 로슈 아게 Ｍｇｌｕｒ2 길항제로서 옥사다이아졸일 피라졸로-피리미딘
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP1991528A2 (en) * 2006-01-18 2008-11-19 Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
TWI425917B (zh) 2006-04-21 2014-02-11 Senomyx Inc 包含高度鮮味風味劑之可食用組合物及其製造方法
US7429589B2 (en) 2006-04-27 2008-09-30 Hoffmann-La Roche Inc. Mono-nitration of aromatic compounds via nitrate salts
EP2027132B1 (en) * 2006-05-18 2010-09-15 F. Hoffmann-La Roche AG Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
GB0612428D0 (en) * 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
WO2008077809A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Process for the manufacture of 7-oxa-bicyclo derivatives
WO2008098851A1 (en) * 2007-02-14 2008-08-21 Basf Se Electroluminescent metal complex
EP2142529B1 (en) * 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
AU2008279169A1 (en) * 2007-07-23 2009-01-29 Biotie Therapies, Inc 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
US7913765B2 (en) * 2007-10-19 2011-03-29 Baker Hughes Incorporated Water absorbing or dissolving materials used as an in-flow control device and method of use
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
KR101064258B1 (ko) 2008-12-29 2011-09-14 한국과학기술연구원 벤조아릴우레이도 화합물, 및 이를 함유하는 퇴행성 뇌질환예방 또는 치료용 조성물
US8168785B2 (en) 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
WO2010150927A1 (en) * 2009-06-25 2010-12-29 Sk Holdings Co., Ltd. Pharmaceutical composition for prevention and treatment of cancer diseases comprising benzamide derivatives
RU2455293C2 (ru) * 2010-09-15 2012-07-10 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) N-(2-бензотиазолил)амид 3-бром-2,4-диоксо-4-(4-метоксифенил)бутановой кислоты, обладающий гипогликемической активностью
RU2448100C1 (ru) * 2010-09-24 2012-04-20 Татьяна Николаевна Иванова Производные 2-аминобензотиазола, обладающие противогипоксической активностью, и способ их использования
EP2630144B1 (en) * 2010-10-19 2016-09-07 Boehringer Ingelheim International GmbH Rho kinase inhibitors
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
CN105693712A (zh) 2011-06-22 2016-06-22 普渡制药公司 包含二羟基取代基的trpv1拮抗剂及其用途
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
CN103772376B (zh) * 2012-10-24 2017-01-11 中国医学科学院医药生物技术研究所 取代的苯并-1,3-杂唑类化合物、其制备方法及用途
JP6578349B2 (ja) 2014-08-11 2019-09-18 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
WO2016109492A1 (en) * 2014-12-31 2016-07-07 Angion Biomedica Corp Methods and agents for treating disease
WO2017066225A1 (en) * 2015-10-14 2017-04-20 Texas Tech University System Pharmacoperones of the v2 receptor
EP3512602B1 (en) * 2016-09-16 2024-03-27 HSF Pharmaceuticals Inhibitors of heat shock factors (hsf) and uses thereof
EP3661941B1 (en) * 2017-08-01 2022-12-14 Merck Patent GmbH Thiazolopyridine derivatives as adenosine receptor antagonists
JP6836693B2 (ja) * 2017-09-28 2021-03-03 シーストーン・ファーマスーティカルズ・（スージョウ）・カンパニー・リミテッドＣｓｔｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ （Ｓｕｚｈｏｕ） Ｃｏ．， Ｌｔｄ． Ａ２ａ受容体アンタゴニストとしての縮合環誘導体
AR117844A1 (es) * 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
DE102019110904B4 (de) * 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
CN115151536A (zh) * 2019-12-16 2022-10-04 不列颠哥伦比亚大学 抗病毒化合物、组合物及使用方法
WO2021247921A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Benzothiazole compounds and uses thereof
JP2024505537A (ja) * 2021-01-29 2024-02-06 コリア リサーチ インスティチュート オブ ケミカル テクノロジー ベンゾチアゾール及びベンズイミダゾール誘導体、薬学的に許容可能な塩、その製造方法及びそれを有効成分として含む医薬組成物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505543A (de) * 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
GB1318291A (en) * 1970-04-15 1973-05-23 Shell Int Research Carboxamide derivatives and fungicidal compositions containing them
LU63457A1 (da) * 1970-07-06 1971-11-12
JPS5516147B2 (da) * 1971-12-24 1980-04-30
US4028374A (en) * 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
DE2656468A1 (de) * 1976-12-14 1978-06-15 Boehringer Mannheim Gmbh N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung
US4471957A (en) * 1979-12-03 1984-09-18 Baltimore Therapeutic Equipment Company Method and apparatus for rehabilitation of damaged limbs
CA1153867A (en) 1980-05-16 1983-09-20 Michael A. M. Boersma Process for the preparation of crystalline silicates, crystalline silicates so prepared and process for carrying out catalytic reactions
KR930005004B1 (ko) * 1985-04-15 1993-06-11 쟈안센 파아마슈우티카 엔. 부이. 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
EP0300688A1 (en) * 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
US5348519A (en) * 1988-02-04 1994-09-20 Loredan Biomedical, Inc. Exercise and diagnostic apparatus and method
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
JPH0667923B2 (ja) 1989-05-11 1994-08-31 東洋紡績株式会社 新規なベンゾチアゾール誘導体
WO1990015801A1 (en) * 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
ES2062248T3 (es) 1989-11-10 1994-12-16 Agrolinz Agrarchemikalien Procedimiento para la obtencion de ureas puras, asimetricamente disubstituidas.
US5142910A (en) * 1990-06-27 1992-09-01 Occupational Orthopaedic Systems, Inc. Dynamic physiological function testing apparatus and method
ES2082232T3 (es) * 1990-10-15 1996-03-16 Pfizer Derivados de pirrolidina diona.
US5275045A (en) * 1991-03-07 1994-01-04 Isotechnologies, Inc. Apparatus and method for use in assessing the lifting capability of a human subject
MX9202022A (es) * 1991-05-01 1992-11-01 Otsuka Pharma Co Ltd Derivados de pirazina y proceso para su preparacion.
PT604657E (pt) * 1992-05-21 2000-04-28 Otsuka Pharma Co Ltd Derivado de diester fosfonico
US5312107A (en) * 1993-05-13 1994-05-17 Kordun, Ltd. Golf club swing training and exercise device
JPH0725858A (ja) * 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
JPH0940646A (ja) * 1995-07-27 1997-02-10 Yamanouchi Pharmaceut Co Ltd ベンゼン縮合環誘導体又はその塩
FR2753970B1 (fr) * 1996-10-01 1998-10-30 Synthelabo Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
JPH11130761A (ja) * 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
HUP0102101A3 (en) * 1997-11-10 2002-11-28 Bristol Myers Squibb Co Protein tyrosine kinase inhibitor benzothiazole derivatives and pharmaceutical compositions containing them
WO1999031096A1 (en) * 1997-12-18 1999-06-24 Shaman Pharmaceuticals, Inc. Piperazine derivatives useful as hypoglycemic agents
CN1288462A (zh) * 1998-01-23 2001-03-21 法玛西雅厄普约翰美国公司 噁唑烷酮组合库、组合物和制备方法
JP2002525373A (ja) 1998-09-30 2002-08-13 ニューロゲン コーポレイション ２−ピペラジノアルキルアミノベンゾアゾール誘導体：ドーパミン受容体サブタイプ特殊リガンド
UA71587C2 (uk) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
EP1140905B1 (en) * 1998-12-23 2003-05-14 Eli Lilly And Company Heteroaromatic amides as inhibitor of factor xa
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
WO2001044178A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel urea compounds, compositions and methods of use and preparation
AU8181701A (en) * 2000-06-21 2002-01-02 Hoffmann La Roche Benzothiazole derivatives
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives

Also Published As

Publication number Publication date
US20080108809A1 (en) 2008-05-08
AU8181701A (en) 2002-01-02
KR100526487B1 (ko) 2005-11-08
NO20073465L (no) 2002-12-12
JP3886897B2 (ja) 2007-02-28
US20030176695A1 (en) 2003-09-18
CA2413086C (en) 2011-06-28
CA2413086A1 (en) 2001-12-27
US6963000B2 (en) 2005-11-08
DE60132777D1 (de) 2008-03-27
US20080125419A1 (en) 2008-05-29
ZA200209730B (en) 2004-03-01
US20060003986A1 (en) 2006-01-05
YU96502A (sh) 2006-01-16
US20100075959A1 (en) 2010-03-25
HRP20020962A2 (en) 2005-02-28
CZ2003182A3 (cs) 2003-06-18
US20030125318A1 (en) 2003-07-03
IL153278A0 (en) 2003-07-06
KR20050043912A (ko) 2005-05-11
DE60132777T2 (de) 2009-02-12
BR0112395A (pt) 2003-07-08
US6521754B2 (en) 2003-02-18
AR031244A1 (es) 2003-09-17
KR20030019446A (ko) 2003-03-06
EP1303272A2 (en) 2003-04-23
PE20020104A1 (es) 2002-02-16
NO324635B1 (no) 2007-11-26
HUP0301315A2 (hu) 2003-08-28
EP1797878A3 (en) 2010-01-20
PL207384B1 (pl) 2010-12-31
US7317007B2 (en) 2008-01-08
NO20025978L (no) 2002-12-12
RU2251419C2 (ru) 2005-05-10
EP1797878A2 (en) 2007-06-20
WO2001097786A2 (en) 2001-12-27
AU2001281817B2 (en) 2005-11-24
HK1058148A1 (en) 2004-05-07
US20050026906A1 (en) 2005-02-03
WO2001097786A3 (en) 2002-12-12
PL360697A1 (en) 2004-09-20
CN1437471A (zh) 2003-08-20
HUP0301315A3 (en) 2007-10-29
ES2299504T3 (es) 2008-06-01
MY138352A (en) 2009-05-29
KR100571161B1 (ko) 2006-04-17
MXPA02012596A (es) 2003-04-10
IL153278A (en) 2012-12-31
CN1234358C (zh) 2006-01-04
JP2003535887A (ja) 2003-12-02
NZ522928A (en) 2005-05-27
US6835732B2 (en) 2004-12-28
ECSP024399A (es) 2003-02-06
CY1107401T1 (el) 2012-12-19
NO20025978D0 (no) 2002-12-12
ATE385794T1 (de) 2008-03-15
EP1303272B1 (en) 2008-02-13
SI1303272T1 (sl) 2008-06-30
UY26782A1 (es) 2001-12-28
PT1303272E (pt) 2008-04-14
JO2503B1 (en) 2009-10-05
US20020045615A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
DK1303272T3 (da) Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom
DK1443955T3 (da) PDGF-BB til behandling af Parkinsons sygdom
NO20026199L (no) Forbindelser for behandling av Alzheimers sykdom
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
DK1224297T3 (da) Alzheimers sygdom -sekretase, APP-substrater derfor og anvendelser deraf
NO20054640D0 (no) Fremgangsmater for behandling av Parkinsons sykdom
DK2527315T3 (da) Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1944040T3 (da) Analysefremgangsmåde for Alzheimers sygdom
MA27083A1 (fr) Derives de nicotine ou d'isonicotine benzothiazole
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
DK1334091T3 (da) Thioflavinderivater og deres anvendelse til diagnose og terapi af Alzheimer's sygdom
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
NO20040198L (no) Dolastatin 10 derivater
NO20032007L (no) Radiofarmasöytika for diagnostisering av Alzheimers sykdom
DK2172208T3 (da) Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser
IS6917A (is) Epóþílon afleiður til meðhöndlunar erfiðra æxla
DK1165510T3 (da) 1-arensulfonyl-2-aryl-pyrrolidin- og -piperidinderivater til behandling af CNS-lidelser
NO20054714D0 (no) Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom
NO20040659D0 (no) Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom
AU2003303141A8 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
ATE330603T1 (de) Benzothiazolderivaten
NO20024746D0 (no) Anvendelse av galantamin ved behandling av nevropsykiatrisk oppförsel assosiert med Alzheimers sykdom